Simultaneous determination of clopidogrel, 2-oxo-clopidogrel, and the thiol metabolite of clopidogrel in human plasma by LC-MS/MS
Open Access
- 1 January 2022
- journal article
- research article
- Published by Journal of Biomedical Research in Journal of Biomedical Research
- Vol. 36 (2) , 109-119
Abstract
Clopidogrel is a pro-drug which needs two-step metabolism to produce the active thiol metabolite. This study aimed to explore an efficient method to simultaneously determine the plasma clopidogrel, 2-oxo-clopidogrel (2-Oxo-CLP), and the clopidogrel active metabolite (CAM). A high-throughput liquid chromatography tandem mass spectrometry (LC-MS/MS) was therefore developed. The analytes were extracted from plasma by using methyl tert-butyl ether (MTBE). Chromatographic separation was performed on a C18 column under an isocratic elution, accompanied with acetonitrile and deionized water containing 0.1% formic acid. After optimizing the condition of LC-MS/MS, a stable linearity was observed in the standard curves over the concentration ranges of 0.05 to 50.0 ng/mL for clopidogrel, 0.5 to 50.0 ng/mL for 2-Oxo-CLP, and 0.5 to 100 ng/mL for clopidogrel active metabolite derivative (CAMD). The retention time was 4.78 minutes, 3.79 minutes, 3.59 minutes, and 4.82 minutes for clopidogrel, 2-Oxo-CLP, CAMD, and internal standard, respectively. Both the relative standard deviation and the relative error were within the requirement of operating criteria. No significant degradation of clopidogrel, 2-Oxo-CLP, and CAMD occurred under different storage conditions. This method was successfully validated in 3 patients with coronary artery disease. The results showed that the current LC-MS/MS method was efficient for simultaneously detecting clopidogrel, 2-Oxo-CLP, and CAM with fine linearity, accuracy, precision, and stability.Keywords
This publication has 26 references indexed in Scilit:
- A sensitive and rapid ultra HPLC–MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasmaJournal of Chromatography B, 2011
- Genetic determinants of platelet response to clopidogrelJournal of Thrombosis and Thrombolysis, 2011
- An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasmaThrombosis and Haemostasis, 2011
- Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCIJAMA, 2010
- Clopidogrel pathwayPharmacogenetics and Genomics, 2010
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2010
- Quantitative determination of clopidogrel active metabolite in human plasma by LC–MS/MSJournal of Pharmaceutical and Biomedical Analysis, 2008
- Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl AlcoholThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Clopidogrel for Coronary StentingCirculation, 2003
- ClopidogrelDrugs, 1997